Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on May 7, 2020. The filing serves to announce the company's financial results for the quarter ended March 31, 2020. The registrant is an emerging growth company incorporated in Delaware with its principal executive offices in Cincinnati, Ohio.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is not included in the source text.
Material Changes
The filing does not provide specific data regarding material changes versus the prior comparable period. It only confirms the announcement of the Q1 2020 results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information under Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, it is not subject to the liabilities of that section nor incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 press release.
- Confirm the company name is Aerpio Pharmaceuticals, Inc. (Ticker: ARPO), as the input metadata incorrectly listed Whitehawk Therapeutics, Inc.
- Review the full press release for any updates on clinical trial progress or operational milestones not captured in this summary.
- Check subsequent filings for any restatements or updates to the Q1 2020 results.